Abstract
Purpose
The continuous growth of antidepressant consumption and expenditure, especially for selective serotonin reuptake inhibitors (SSRIs), has led to the adoption of several policy measures directed toward cost control in Western countries. In Italy, copayment policies have been heterogeneously introduced at a regional level as part of a strategy designed to reduce drug consumption. The aim of our study was to evaluate whether regional copayment policies have affected trends in the consumption of and expenditure for SSRIs from 2001 to 2007.
Methods
The consumption of SSRIs was measured in terms of defined daily doses per 1,000 inhabitants (DDD/1000) per day from May 2001 to December 2007. Time trends in consumption and expenditure before and after the introduction of copayment policies were examined using segmented regression analysis of interrupted time-series, adjusting for seasonal components. The study was conducted for 17 regions, nine of which had implemented a copayment policy.
Results
The overall consumption of SSRIs in Italy increased during the study period, from a monthly consumption of 12.85 DDD/1000 per day in May 2001 to 23.40 DDD/1000 per day in December 2007. The average monthly increase in SSRI use was 0.82 % in regions with a copayment policy versus 0.77 % in regions without a copayment policy (P = 0.329). According to the multivariable analysis, copayment was associated with a 1 % reduction in the monthly growth rate of SSRI consumption (P = 0.01). The impact of copayment on expenditure was statistically significant (P < 0.005) on both the level and the trend, even though the estimate of the effect was negligible.
Conclusions
The implementation of copayment policies in Italy affected both the use and expenditure of SSRIs between 2001 and 2007 to only to a minor extent.
Similar content being viewed by others
References
Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ (2004) Global burden of depressive disorders in the year 2000. Br J Psychiatry 184:386–392. doi:10.1192/bjp. 184.5.386
Murray CJL, Lopez AD (1996) The global burden of disease and injury series, volume 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard University Press, Cambridge
World Health Organization (2004) The global burden of disease: 2004 update. Available at: http://www.who.int/entity/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf. Accessed 1 July 2012
OECD (2009) Health at a Glance 2009: OECD indicators. OECD Publishing, Paris. doi: 10.1787/health_glance-2009-en. http://www.oecd-ilibrary.org/docserver/download/fulltext/8109111e.pdf?expires=1337072474&id=id&accname=guest&checksum=2FE8066C18AA1BE2924D9F59C915A78F. Accessed 1 July 2012
Meredith LS, Branstrom RB, Azocar F, Fikes R, Ettner SL (2011) A collaborative approach to identifying effective incentives for mental health clinicians to improve depression care in a large managed behavioral healthcare organization. Adm Policy Ment Health 38:193–202. doi:10.1007/s10488-010-0313-0
Lacasse JR, Leo J (2006) Questionable advertising of psychotropic medications and disease mongering. PLoS Med 3(7):e321. doi:10.1371/journal.pmed.0030321
Gruppo di lavoro OsMed (2003) L’uso dei farmaci in Italia. Rapporto nazionale anno 2002. Il Pensiero Scientifico Editore, Roma [OsMed Working Team. The drug utilisation in Italy, National Reports 2002]. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/111.93135.1150790141602c1dc.pdf. Accessed 1 July 2012
Gruppo di lavoro OsMed (2008) L’uso dei farmaci in Italia. Rapporto nazionale anno 2007. Roma: Il Pensiero Scientifico Editore, Roma. [OsMed Working Team. The drug utilisation in Italy, National Reports 2007]. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/rapporto_osmed_2007_0.pdf. Accessed 1 July 2012
Percudani M, Barbui C, Fortino I, Petrovich L (2004) Antidepressant drug use in Lombardy, Italy: a population-based study. J Affect Disord 83(2–3):169–75. doi:10.1016/j.jad.2004.07.005
Trifirò G, Barbui C, Spina E, Moretti S, Tari M, Alacqua M, Caputi AP, Arcoraci V, UVEC group (2007) Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003–2004. Pharmacoepidemiol Drug Saf 16(5):552–9. doi:10.1002/pds.1303
Dunn JD, Cannon HC, Mitchell MP, Curtiss FR (2006) Utilization and Drug Cost Outcomes of a Step-Therapy Edit for Generic Antidepressants in a HMO in an Integrated Health System. J Manag Care Pharm 12(4):294–302
Hodgkin D, Horgan CM, Garnick DW, Len Merrick E, Volpe-Vartanian J (2007) Management of access to branded psychotropic medication in private health plans. Clin Ther 29:371–380. doi:10.1016/j.clinthera.2007.02.011
Wang PS, Patrick AR, Dormuth CR, Avorn J, Maclure M, Canning CF, Schneeweiss S (2008) The impact of cost-sharing on antidepressants use among older adults in British Columbia. Psychiatr Serv 59:377–383. doi:10.1176/appi.ps.59.4.377
Fattore G, Torbica A (2005) Health service benefit catalogues in Europe. Country Report: Italy. HealthBASKET Project. Available at: http://www.ehma.org/files/WP_6_HealthBASKETSP21_CT_2004_501588_D15_Italy.pdf. Accessed 15 Sept 2012
Poluzzi E, Motola D, Silvani C, De Ponti F, Vaccheri A, Montanaro M (2004) Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement. Eur J Clin Pharmacol 59(11):825–31. doi:10.1007/s00228-003-0692-1
Torbica A, Fattore G (2005) The “Essential Levels of Care” in Italy: when being explicit serves the devolution of powers. Eur J Health Econom 6[Suppl 1]:46-52. doi:10.1007/s10198-005-0318-x
Fattore G, Jommi C (2008) The last decade of Italian pharmaceutical policy: instability or consolidation? Pharmacoeconomics 26(1):5–15
Mapelli V, Lucioni C (2003) Spending on pharmaceuticals in Italy: macro constraints with local autonomy. Value Health 6[Suppl 1]:S31–45. doi:10.1046/j.1524-4733.6.s1.4.x
Fiorio CV, Siciliani L (2010) Co-payments and the demand for pharmaceuticals: evidence from Italy. Econ Model 27:835–41. doi:10.1016/j.econmod.2009.07.019
WHO Collaborating Centre for Drug Statistics Methodology (2010) Guidelines for ATC classification and DDD assignment 2011. Available at: http://www.whocc.no/filearchive/publications/2011guidelines.pdf. Accessed 15 Sept 2012
Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D (2002) Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 27(4):299–309. doi:10.1046/j.1365-2710.2002.00430.x
Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsey C, Oxman AD, Sturm H, Kosters JP, Vernby A (2008) Pharmaceutical policies: effects of cap and co-payment on rational drug use (Review). Cochrane Database Syst Rev 23(1):CD007017
Hosmer W, Lemeshow S (2000) Applied logistic regression, 2nd edn. Wiley, New York
Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML (2005) Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manag Care 11(10):621–628
Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, Landsman PB, Teutsch SM (2004) Pharmacy benefits and the use of drugs by the chronically ill. JAMA 291(19):2344–2350. doi:10.1001/jama.291.19.2344
Ong M, Catalano R, Harting T (2003) A time-series analysis of the effect of increased copayments on the prescription of antidepressants, anxiolytics, and sedatives in Sweden from 1990 to 1999. Clin Ther 25(4):1262–1275. doi:10.1016/S0149-2918(03)80082-6
Goldman DP, Joyce GF, Zheng Y (2007) Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 298(1):61–69. doi:10.1001/jama.298.1.61
Stevenson FA, Greenfield SM, Jones M, Nayak A, Bradley CP (1999) GPs' perceptions of patient influence on prescribing. Fam Pract 16:255–61
Sleath B, Shih YC (2003) Sociological influences on antidepressant prescribing. Soc Sci Med 56(6):1335–44. doi:10.1016/S0277-9536(02)00132-6
Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG (2004) Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 42(12):1176–85
Dewa CS, Hoch JS, Goering P (2008) Previous out-of-pocket drug expenditures and patterns of antidepressant use among workers receiving depression-related disability benefits. Healthc Policy 4(2):e149–e166
Pichetti S, Sorasith C, Sermet C (2011) Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: a time series analysis for France 1998-2010. Health Policy 102(2–3):159–169. doi:10.1016/j.healthpol.2011.07.001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Damiani, G., Federico, B., Silvestrini, G. et al. Impact of regional copayment policy on selective serotonin reuptake inhibitor (SSRI) consumption and expenditure in Italy. Eur J Clin Pharmacol 69, 957–963 (2013). https://doi.org/10.1007/s00228-012-1422-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-012-1422-3